Security
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares · KNSA
KNSANASDAQCommon stockCurrentCIK 1730430Updated Nov 1, 2026
Name history
Kiniksa Pharmaceuticals, Ltd. · through Jun 28, 2024
KNSA price & chart
Loading TradingView…
NASDAQ:KNSA on TradingView ↗About the company
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.
In the news
No coverage from other publishers is available.
Recent filings
144 filing
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 712,333,000Source | 555,298,000Source | 483,063,000Source | 661,150,000Source | 542,428,000Source | 825,280,000Source | 599,326,000Source | 519,673,000Source | 763,633,000Source | 580,553,000Source | 526,322,000Source | 459,672,000Source |
| Property, Plant and Equipment, NetUSD | 1,655,000Source | 561,000Source | 918,000Source | 1,076,000Source | 625,000Source | 1,986,000Source | 606,000Source | 712,000Source | 1,943,000Source | 662,000Source | 734,000Source | 1,658,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 174,858,000Source | 97,376,000Source | 117,828,000Source | 192,037,000Source | 99,271,000Source | 189,952,000Source | 157,132,000Source | 141,078,000Source | 165,596,000Source | 183,581,000Source | 107,954,000Source | 122,715,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 51,742,000Source | 24,888,000Source | 3,041,000Source | 31,910,000Source | 20,451,000Source | 23,224,000Source | 40,065,000Source | 15,995,000Source | 15,594,000Source | 41,724,000Source | 21,266,000Source | 12,660,000Source |
| Inventory, NetUSD | 41,396,000Source | 28,680,000Source | 25,583,000Source | 48,181,000Source | 34,858,000Source | 73,141,000Source | 22,069,000Source | 27,278,000Source | 54,895,000Source | 26,364,000Source | 31,122,000Source | 21,599,000Source |
| Assets, CurrentUSD | 475,530,000Source | 311,301,000Source | 256,109,000Source | 420,311,000Source | 301,021,000Source | 594,172,000Source | 355,907,000Source | 270,591,000Source | 527,177,000Source | 331,799,000Source | 276,297,000Source | 243,060,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 30,290,000Source | 33,953,000Source | 26,401,000Source | 32,438,000Source | 26,954,000Source | 29,714,000Source | 25,433,000Source | 13,766,000Source | 42,614,000Source | 20,084,000Source | 17,538,000Source | 10,537,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,073,000Source | 11,095,000Source | 12,668,000Source | 10,304,000Source | 11,779,000Source | 9,334,000Source | 10,453,000Source | 12,324,000Source | 9,807,000Source | 10,376,000Source | 11,931,000Source | 5,385,000Source |
| Other Assets, NoncurrentUSD | 8,288,000Source | 7,853,000Source | 2,294,000Source | 8,195,000Source | 7,904,000Source | 11,162,000Source | 8,202,000Source | 4,128,000Source | 11,307,000Source | 10,315,000Source | 827,000Source | 5,824,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 176,950,000Source | 118,292,000Source | 77,936,000Source | 166,143,000Source | 107,333,000Source | 219,593,000Source | 141,837,000Source | 87,778,000Source | 196,027,000Source | 142,117,000Source | 87,483,000Source | 63,523,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 1,011,854,000Source | 949,282,000Source | 908,295,000Source | 989,811,000Source | 934,767,000Source | 1,045,877,000Source | 970,238,000Source | 927,582,000Source | 1,029,748,000Source | 959,722,000Source | 916,763,000Source | 888,120,000Source |
| Retained Earnings (Accumulated Deficit)USD | -476,337,000Source | -512,255,000Source | -503,187,000Source | -494,772,000Source | -499,562,000Source | -439,546,000Source | -512,604,000Source | -495,654,000Source | -462,138,000Source | -521,143,000Source | -477,950,000Source | -492,034,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -155,000Source | -41,000Source | -1,000Source | -53,000Source | -130,000Source | -665,000Source | -165,000Source | -53,000Source | -25,000Source | -163,000Source | 6,000Source | 44,000Source |
| Stockholders' Equity Attributable to ParentUSD | 535,383,000Source | 437,006,000Source | 405,127,000Source | 495,007,000Source | 435,095,000Source | 605,687,000Source | 457,489,000Source | 431,895,000Source | 567,606,000Source | 438,436,000Source | 438,839,000Source | 396,149,000Source |
| Liabilities and EquityUSD | 712,333,000Source | 555,298,000Source | 483,063,000Source | 661,150,000Source | 542,428,000Source | 825,280,000Source | 599,326,000Source | 519,673,000Source | 763,633,000Source | 580,553,000Source | 526,322,000Source | 459,672,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 123,592,000Source | 95,955,000Source | 53,468,000Source | 117,827,000Source | 84,291,000Source | 156,611,000Source | 97,267,000Source | 64,212,000Source | 139,184,000Source | 100,621,000Source | 63,666,000Source | 47,066,000Source |
| Operating Lease, Liability, CurrentUSD | 2,696,000Source | 2,031,000Source | 2,313,000Source | 2,522,000Source | 2,085,000Source | 3,170,000Source | 2,292,000Source | 2,279,000Source | 2,987,000Source | 1,993,000Source | 2,253,000Source | 3,301,000Source |
| Accounts Payable, CurrentUSD | 6,150,000Source | 8,328,000Source | 1,012,000Source | 8,956,000Source | 7,393,000Source | 24,402,000Source | 1,982,000Source | 5,632,000Source | 2,028,000Source | 2,039,000Source | 8,246,000Source | 7,899,000Source |
| Operating Lease, Liability, NoncurrentUSD | 7,022,000Source | 8,564,000Source | 10,651,000Source | 7,243,000Source | 9,317,000Source | 5,855,000Source | 7,623,000Source | 9,864,000Source | 6,510,000Source | 7,862,000Source | 10,005,000Source | 2,618,000Source |
| Other Liabilities, NoncurrentUSD | 14,525,000Source | 1,962,000Source | 1,945,000Source | 9,262,000Source | 1,926,000Source | 25,316,000Source | 5,136,000Source | 1,891,000Source | 18,522,000Source | 1,823,000Source | 1,858,000Source | 1,839,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 30,941,000Source | 40,379,000Source | 41,149,000Source | 35,959,000Source | 33,374,000Source | 32,771,000Source | 22,126,000Source | 44,718,000Source | 42,020,000Source | 32,355,000Source | 44,667,000Source | 30,112,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 352,102,000Source | 223,780,000Source | 201,084,000Source | 307,782,000Source | 218,758,000Source | — | 268,340,000Source | 213,552,000Source | 414,074,000Source | 243,627,000Source | 206,371,000Source | 190,608,000Source |
| Short-term InvestmentsUSD | 177,244,000Source | 126,404,000Source | 83,256,000Source | 115,745,000Source | 119,487,000Source | 278,141,000Source | 111,208,000Source | 72,474,000Source | 248,478,000Source | 60,046,000Source | 98,417,000Source | 67,893,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 22,592,000Source | 8,539,000Source | 59,005,000Source | -43,193,000Source | 14,084,000Source | 183,363,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 10,144,000Source | 7,826,000Source | — | — | 10,056,000Source | 7,748,000Source | 37,003,000Source | 30,693,000Source | 27,149,000Source | 25,120,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 7,630,000Source | -1,659,000Source | -26,130,000Source | 20,458,000Source | 8,606,000Source | 8,675,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 18,246,000Source | -4,295,000Source | 28,531,000Source | -4,758,000Source | 9,523,000Source | 17,924,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 22,266,000Source | 62,000Source | 142,000Source | -6,306,000Source | 347,000Source | 6,031,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | 4,227,000Source | -3,639,000Source | — | — | 4,523,000Source | 2,993,000Source | 13,002,000Source | 8,132,000Source | -33,788,000Source | -185,495,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 50,199,000Source | 22,324,000Source | 137,985,000Source | 25,689,000Source | 13,301,000Source | 5,807,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -31,916,000Source | -51,541,000Source | -188,993,000Source | 37,672,000Source | -29,557,000Source | -8,078,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 161,000Source | 99,000Source | 1,568,000Source | 277,000Source | 130,000Source | 105,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 316,000Source | 412,000Source | 7,730,000Source | 4,984,000Source | 2,206,000Source | 901,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,073,000Source | 2,768,000Source | 33,023,000Source | 12,266,000Source | 1,495,000Source | 2,516,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 174,858,000Source | 97,376,000Source | 192,037,000Source | 99,271,000Source | 189,952,000Source | 157,132,000Source | 165,596,000Source | 183,581,000Source | 107,954,000Source | 122,715,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 3,008,000Source | 3,012,000Source | 2,003,000Source | 5,605,000Source | 10,689,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 10,144,000Source | 7,826,000Source | 8,876,000Source | 7,363,000Source | 10,056,000Source | 7,748,000Source | 37,003,000Source | 30,693,000Source | 27,149,000Source | 25,120,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 352,102,000Source | 223,780,000Source | 307,782,000Source | 218,758,000Source | — | 268,340,000Source | 414,074,000Source | 243,627,000Source | 206,371,000Source | 190,608,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| DepreciationUSD | — | — | 27,000Source | 87,000Source | 13,000Source | 119,000Source | 144,000Source | 35,000Source | 196,000Source | 448,000Source | 1,109,000Source | 1,179,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 54,000Source | -10,000Source | 120,000Source | -1,000Source | -179,000Source | -33,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,722,000Source | 5,492,000Source | 5,045,000Source | 6,212,000Source | 10,089,000Source | 7,026,000Source | 29,863,000Source | 7,041,000Source | -30,736,000Source | -172,337,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 11,636,000Source | 9,036,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 18,435,000Source | -12,693,000Source | 17,832,000Source | -3,908,000Source | 22,592,000Source | 8,539,000Source | 59,005,000Source | -43,193,000Source | 14,084,000Source | 183,363,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 2,876,000Source | 2,606,000Source |
| Amortization of Intangible Assets | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 180,855,000Source | 112,214,000Source | 156,797,000Source | 108,631,000Source | 214,266,000Source | 137,785,000Source | 677,564,000Source | 423,239,000Source | 270,259,000Source | 220,180,000Source |
| Cost of RevenueUSD | — | — | 20,257,000Source | 20,109,000Source | 18,603,000Source | 12,322,000Source | 20,796,000Source | 17,868,000Source | 77,673,000Source | 60,910,000Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 49,104,000Source | 46,399,000Source | 46,863,000Source | 42,395,000Source | 61,151,000Source | 43,530,000Source | 196,272,000Source | 168,011,000Source | 129,427,000Source | 97,951,000Source |
| Operating Income (Loss)USD | — | — | 24,021,000Source | -9,658,000Source | 20,160,000Source | -117,000Source | 29,267,000Source | 13,272,000Source | 77,221,000Source | -45,616,000Source | -25,196,000Source | 9,773,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 27,157,000Source | -7,201,000Source | 22,877,000Source | 2,304,000Source | 32,681,000Source | 15,565,000Source | 88,868,000Source | -36,152,000Source | -16,652,000Source | 11,026,000Source |
| Income Tax Expense (Benefit)USD | — | — | 8,722,000Source | 5,492,000Source | 5,045,000Source | 6,212,000Source | 10,089,000Source | 7,026,000Source | 29,863,000Source | 7,041,000Source | -30,736,000Source | -172,337,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 18,435,000Source | -12,693,000Source | 17,832,000Source | -3,908,000Source | 22,592,000Source | 8,539,000Source | 59,005,000Source | -43,193,000Source | 14,084,000Source | 183,363,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.25Source | -0.18Source | 0.24Source | -0.06Source | 0.3Source | 0.12Source | 0.8Source | -0.6Source | 0.2Source | 2.64Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.23Source | -0.18Source | 0.23Source | -0.06Source | 0.27Source | 0.11Source | 0.75Source | -0.6Source | 0.2Source | 2.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 74,714,846Source | 71,726,685Source | 73,438,530Source | 71,004,640Source | 76,516,535Source | 72,647,121Source | 74,200,924Source | 71,424,159Source | 70,058,952Source | 69,382,275Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 80,035,400Source | 71,726,685Source | 77,942,082Source | 71,004,640Source | 82,409,703Source | 76,145,617Source | 78,979,030Source | 71,424,159Source | 71,922,915Source | 70,421,322Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 16,861,000Source | -1,091,000Source | 3,052,000Source | 13,158,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 468,000Source | 345,000Source | 1,554,000Source | 1,695,000Source | 2,341,000Source | 2,402,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 2,775,000Source | -7,674,000Source | -91,133,000Source | -84,067,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 11,636,000Source | 9,036,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 24,166,000Source | 26,057,000Source | 18,753,000Source | 24,017,000Source | 27,475,000Source | 19,325,000Source | 96,853,000Source | 111,623,000Source | 76,097,000Source | 65,490,000Source |
| Amortization of Intangible Assets | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
knsa-ex99d1.htm · 8-K · 2026-10-27
Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution - ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth - - ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion - - KPL-387 pivotal Phase 3 data expected in 2H 2027 - - Conference call and webcast scheduled for 8:30 am ET today - London - October 27, 2026 - Kiniksa Pharmaceuticals International, …
Read attachment ↗knsa-20260728xex99d1.htm · 8-K · 2026-07-28
EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution - ARCALYST® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth - - ARCALYST 2026 expected net product revenue increased to $980 - $995 million - - KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selecte…
Read attachment ↗tm2615425d1_ex99-1.htm · SCHEDULE 13D/A · 2026-05-26
Exhibit 99.1 Holder Class A Class A1 Class B1 ordinary shares ordinary shares ordinary shares ───────────────────────────────────────────────────────────────────────────────────────────────────── 667, L.P. 98,980 1,143,650 1,399,516 Baker Brothers Life Sciences, L.P. 2,700,597 11,638,314 …
Read attachment ↗knsa-20260428xex99d1.htm · 8-K · 2026-04-28
EX-99.1 2 knsa-20260428xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution - ARCALYST® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth - - ARCALYST 2026 expected net product revenue increased to $930 - $945 million - - KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end - - Q1 2026 cash bal…
Read attachment ↗knsa-20260224xex99d1.htm · 8-K · 2026-02-24
EX-99.1 2 knsa-20260224xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution - ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively - - ARCALYST 2026 net product revenue expected to be $900 - $920 million - - KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 - - KPL-1161 Phase 1 trial planned to initiate by the en…
Read attachment ↗knsa-20260112xex99d1.htm · 8-K · 2026-01-12
EX-99.1 2 knsa-20260112xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Provides Corporate Update - ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth - - ARCALYST 2026 net product revenue expected to be $900 - $920 million - - KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 - - KPL-1161 Phase 1 trial planned to initiate by year end - - Cash balance increased by $170.4 million in 2025 to $414.1 …
Read attachment ↗